177 related articles for article (PubMed ID: 19951976)
1. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.
Kienle D; Benner A; Läufle C; Winkler D; Schneider C; Bühler A; Zenz T; Habermann A; Jäger U; Lichter P; Dalla-Favera R; Döhner H; Stilgenbauer S
Haematologica; 2010 Jan; 95(1):102-9. PubMed ID: 19951976
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.
van't Veer MB; Brooijmans AM; Langerak AW; Verhaaf B; Goudswaard CS; Graveland WJ; van Lom K; Valk PJ
Haematologica; 2006 Jan; 91(1):56-63. PubMed ID: 16434371
[TBL] [Abstract][Full Text] [Related]
3. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.
Kaderi MA; Kanduri M; Buhl AM; Sevov M; Cahill N; Gunnarsson R; Jansson M; Smedby KE; Hjalgrim H; Jurlander J; Juliusson G; Mansouri L; Rosenquist R
Haematologica; 2011 Aug; 96(8):1153-60. PubMed ID: 21508119
[TBL] [Abstract][Full Text] [Related]
4. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia.
Stamatopoulos B; Meuleman N; Haibe-Kains B; Duvillier H; Massy M; Martiat P; Bron D; Lagneaux L
Clin Chem; 2007 Oct; 53(10):1757-66. PubMed ID: 17702857
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia.
Nückel H; Hüttmann A; Klein-Hitpass L; Schroers R; Führer A; Sellmann L; Dührsen U; Dürig J
Leuk Lymphoma; 2006 Jun; 47(6):1053-61. PubMed ID: 16840197
[TBL] [Abstract][Full Text] [Related]
6. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
7. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.
Admirand JH; Knoblock RJ; Coombes KR; Tam C; Schlette EJ; Wierda WG; Ferrajoli A; O'Brien S; Keating MJ; Luthra R; Medeiros LJ; Abruzzo LV
Mod Pathol; 2010 Nov; 23(11):1518-23. PubMed ID: 20657554
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia.
Van Bockstaele F; Pede V; Janssens A; Callewaert F; Offner F; Verhasselt B; Philippé J
Clin Chem; 2007 Feb; 53(2):204-12. PubMed ID: 17158192
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
[TBL] [Abstract][Full Text] [Related]
11. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
[TBL] [Abstract][Full Text] [Related]
12. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Maloum K; Settegrana C; Chapiro E; Cazin B; Leprêtre S; Delmer A; Leporrier M; Dreyfus B; Tournilhac O; Mahe B; Nguyen-Khac F; Lesty C; Davi F; Merle-Béral H
Ann Hematol; 2009 Dec; 88(12):1215-21. PubMed ID: 19340428
[TBL] [Abstract][Full Text] [Related]
13. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia.
Oppezzo P; Vasconcelos Y; Settegrana C; Jeannel D; Vuillier F; Legarff-Tavernier M; Kimura EY; Bechet S; Dumas G; Brissard M; Merle-Béral H; Yamamoto M; Dighiero G; Davi F;
Blood; 2005 Jul; 106(2):650-7. PubMed ID: 15802535
[TBL] [Abstract][Full Text] [Related]
14. Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.
Tausch E; Mertens D; Stilgenbauer S
Oncol Res Treat; 2016; 39(1-2):34-40. PubMed ID: 26890126
[TBL] [Abstract][Full Text] [Related]
15. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
16. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
[TBL] [Abstract][Full Text] [Related]
17. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
[TBL] [Abstract][Full Text] [Related]
18. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
[TBL] [Abstract][Full Text] [Related]
19. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
